Triple
T32170187
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Alecensa |
E821687
|
entity |
| Predicate | hasClinicalTrial |
P23163
|
FINISHED |
| Object |
ALEX trial
The ALEX trial was a pivotal phase III clinical study that compared alectinib with crizotinib as first-line treatment in patients with ALK-positive advanced non–small cell lung cancer, demonstrating superior efficacy and central nervous system control for alectinib.
|
E1995244
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: ALEX trial | Statement: [Alecensa, hasClinicalTrial, ALEX trial]
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: ALEX trial Triple: [Alecensa, hasClinicalTrial, ALEX trial]
Generated description
The ALEX trial was a pivotal phase III clinical study that compared alectinib with crizotinib as first-line treatment in patients with ALK-positive advanced non–small cell lung cancer, demonstrating superior efficacy and central nervous system control for alectinib.
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69f3490699a48190bbef96b198e8fade |
completed | April 30, 2026, 12:20 p.m. |
| NER | Named-entity recognition | batch_69f6ba73aa9c819082328ddf6ec799ec |
completed | May 3, 2026, 3:01 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_6a2f0bd90ffc819083310e0650e4e1f9 |
completed | June 14, 2026, 8:15 p.m. |
| NEDg | Description generation | batch_6a2f15db9f1c8190852475cbdbafdd67 |
completed | June 14, 2026, 8:58 p.m. |
| NED2 | Entity disambiguation (via description) | batch_6a2f16e68f588190b18717146305a932 |
completed | June 14, 2026, 9:02 p.m. |
Created at: May 1, 2026, 12:33 a.m.